Supplementary figures: Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis

<p dir="ltr"><b>These are peer-reviewed supplementary materials for the article '</b><b>Efficacy and safety of PD-1/PD-L1 and </b><b>CTLA-4 immune checkpoint inhibitors in </b><b>colorectal cancer: a meta-analysis</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b></p><ul><li><b>supplementary figure 1</b></li><li><b>supplementary figure 2</b></li><li><b>supplementary figure 3</b></li><li><b>supplementary figure 4</b></li><li><b>supplementary figure 5</b></li><li><b>supplementary figure 6</b></li><li><b>supplementary figure 7</b></li><li><b>supplementary figure 8</b></li><li><b>supplementary figure 9</b></li></ul><p dir="ltr"><b>Aims:</b> To evaluate the efficacy and safety of PD-1/PD-L1 and/or CTLA-4 inhibitors in the treatment of colorectal cancer (CRC) by meta-analysis. <b>Methods:</b> Electronic databases were searched. Eligible studies included investigations of efficacy and safety of anti-PD-1/PD-L1 or anti-CTLA-4 agents in patients with CRC. Corresponding indicators were calculated. <b>Results:</b> A total of 15 articles were included. The pooled objective response rate, overall survival rate, progression-free survival rate and adverse event rate were 33, 56, 46 and 59%, respectively. The objective response rates for CRC with deficient mismatch repair and CRC with proficient mismatch repair were 43 and 3%, respectively, in patients treated with PD-1 inhibitors. <b>Conclusion:</b> The authors’ study indicates that PD-1/PD-L1 inhibitors manifest promising clinical responses in the treatment of CRC with deficient mismatch repair with acceptable treatment-related adverse events.</p>